FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4315977498> ?p ?o ?g. }

• W4315977498 endingPage "105281" @default.
• W4315977498 startingPage "105281" @default.
• W4315977498 abstract "Preclinical evidence suggests that c-Abl is critical in the pathogenesis of Parkinson's Disease (PD). Vodobatinib (K0706) is a potent, specific Abl kinase inhibitor currently being developed for the treatment of PD. In previously reported studies, nilotinib, a multikinase c-Abl inhibitor, did not show clinical activity as evidenced by no improvement of symptoms or the rate of decline after one to six months of treatment at the maximum permissible dose, presumably because of insufficient CNS penetration. Here we report clinical PK and safety data for vodobatinib.To determine safety, plasma PK, and CSF penetration of vodobatinib in healthy volunteers and PD subjects following oral administration, and compare CSF levels to in vitro concentrations required for c-Abl inhibition relative to data reported for nilotinib.Inhibition of c-Abl kinase activity and c-Abl binding affinity were first assessed in vitro. Healthy human volunteers and PD patients received various oral doses of vodobatinib once-daily for seven and fourteen days respectively, to assess safety, and plasma and CSF PK.In in vitro assays, vodobatinib was more potent (kinase IC50 = 0.9 nM) than nilotinib (kinase IC50 = 15-45 nM). Administration of vodobatinib 48, 192 and 384 mg to healthy subjects for 7 days yielded mean Cmax, CSF values of 1.8, 11.6, and 12.2 nM respectively, with the two highest doses exceeding the IC50 over the entire dosing interval. Cavg, CSF values were 6-8 times greater than the IC50. Comparable CSF levels were observed in PD patients. All doses were well tolerated in both cohorts.Based on achieved CSF concentrations, the potential for c-Abl inhibition in the brain is substantially higher with vodobatinib than with nilotinib. The CSF PK profile of vodobatinib is suitable for determining if c-Abl inhibition will be neuroprotective in PD patients." @default.
• W4315977498 created "2023-01-14" @default.
• W4315977498 creator A5031320105 @default.
• W4315977498 creator A5036832640 @default.
• W4315977498 creator A5045020861 @default.
• W4315977498 creator A5048287204 @default.
• W4315977498 creator A5057266942 @default.
• W4315977498 creator A5063089725 @default.
• W4315977498 creator A5065047026 @default.
• W4315977498 creator A5078232246 @default.
• W4315977498 creator A5086109424 @default.
• W4315977498 date "2023-03-01" @default.
• W4315977498 modified "2023-09-27" @default.
• W4315977498 title "Plasma and cerebrospinal fluid pharmacokinetics of vodobatinib, a neuroprotective c-Abl tyrosine kinase inhibitor for the treatment of Parkinson's disease" @default.
• W4315977498 cites W1986139301 @default.
• W4315977498 cites W1996577359 @default.
• W4315977498 cites W2003247806 @default.
• W4315977498 cites W2097946794 @default.
• W4315977498 cites W2117376526 @default.
• W4315977498 cites W2124196948 @default.
• W4315977498 cites W2134566943 @default.
• W4315977498 cites W2158933399 @default.
• W4315977498 cites W2462137239 @default.
• W4315977498 cites W2470879573 @default.
• W4315977498 cites W2540689820 @default.
• W4315977498 cites W2566920371 @default.
• W4315977498 cites W2955555890 @default.
• W4315977498 cites W2971990973 @default.
• W4315977498 cites W2995537689 @default.
• W4315977498 cites W3022911983 @default.
• W4315977498 cites W3106155982 @default.
• W4315977498 cites W3111927179 @default.
• W4315977498 cites W3112685998 @default.
• W4315977498 cites W3126891350 @default.
• W4315977498 cites W3215211915 @default.
• W4315977498 doi "https://doi.org/10.1016/j.parkreldis.2023.105281" @default.
• W4315977498 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36717298" @default.
• W4315977498 hasPublicationYear "2023" @default.
• W4315977498 type Work @default.
• W4315977498 citedByCount "1" @default.
• W4315977498 countsByYear W43159774982023 @default.
• W4315977498 crossrefType "journal-article" @default.
• W4315977498 hasAuthorship W4315977498A5031320105 @default.
• W4315977498 hasAuthorship W4315977498A5036832640 @default.
• W4315977498 hasAuthorship W4315977498A5045020861 @default.
• W4315977498 hasAuthorship W4315977498A5048287204 @default.
• W4315977498 hasAuthorship W4315977498A5057266942 @default.
• W4315977498 hasAuthorship W4315977498A5063089725 @default.
• W4315977498 hasAuthorship W4315977498A5065047026 @default.
• W4315977498 hasAuthorship W4315977498A5078232246 @default.
• W4315977498 hasAuthorship W4315977498A5086109424 @default.
• W4315977498 hasBestOaLocation W43159774981 @default.
• W4315977498 hasConcept C112705442 @default.
• W4315977498 hasConcept C121608353 @default.
• W4315977498 hasConcept C126322002 @default.
• W4315977498 hasConcept C170493617 @default.
• W4315977498 hasConcept C184235292 @default.
• W4315977498 hasConcept C185592680 @default.
• W4315977498 hasConcept C202751555 @default.
• W4315977498 hasConcept C22979827 @default.
• W4315977498 hasConcept C2777288759 @default.
• W4315977498 hasConcept C2777413986 @default.
• W4315977498 hasConcept C2777752497 @default.
• W4315977498 hasConcept C2778820342 @default.
• W4315977498 hasConcept C42362537 @default.
• W4315977498 hasConcept C55493867 @default.
• W4315977498 hasConcept C71924100 @default.
• W4315977498 hasConcept C98274493 @default.
• W4315977498 hasConceptScore W4315977498C112705442 @default.
• W4315977498 hasConceptScore W4315977498C121608353 @default.
• W4315977498 hasConceptScore W4315977498C126322002 @default.
• W4315977498 hasConceptScore W4315977498C170493617 @default.
• W4315977498 hasConceptScore W4315977498C184235292 @default.
• W4315977498 hasConceptScore W4315977498C185592680 @default.
• W4315977498 hasConceptScore W4315977498C202751555 @default.
• W4315977498 hasConceptScore W4315977498C22979827 @default.
• W4315977498 hasConceptScore W4315977498C2777288759 @default.
• W4315977498 hasConceptScore W4315977498C2777413986 @default.
• W4315977498 hasConceptScore W4315977498C2777752497 @default.
• W4315977498 hasConceptScore W4315977498C2778820342 @default.
• W4315977498 hasConceptScore W4315977498C42362537 @default.
• W4315977498 hasConceptScore W4315977498C55493867 @default.
• W4315977498 hasConceptScore W4315977498C71924100 @default.
• W4315977498 hasConceptScore W4315977498C98274493 @default.
• W4315977498 hasLocation W43159774981 @default.
• W4315977498 hasLocation W43159774982 @default.
• W4315977498 hasOpenAccess W4315977498 @default.
• W4315977498 hasPrimaryLocation W43159774981 @default.
• W4315977498 hasRelatedWork W2029309243 @default.
• W4315977498 hasRelatedWork W2164084739 @default.
• W4315977498 hasRelatedWork W2370929226 @default.
• W4315977498 hasRelatedWork W2379280247 @default.
• W4315977498 hasRelatedWork W2416569285 @default.
• W4315977498 hasRelatedWork W2766550598 @default.
• W4315977498 hasRelatedWork W2942467058 @default.
• W4315977498 hasRelatedWork W3018168093 @default.
• W4315977498 hasRelatedWork W3122926187 @default.
• W4315977498 hasRelatedWork W3151787567 @default.

• next